We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
+5.53%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$2.09B
AUM Growth
+$76.9M
(+3.8%)
Cap. Flow
+$113M
Cap. Flow
% of AUM
5.39%
Top 10 Holdings %
Top 10 Hldgs %
44.54%
Holding
114
New
28
Increased
33
Reduced
17
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$38.4M |
| 2 |
Revolution Medicines
RVMD
|
+$30.3M |
| 3 |
Roivant Sciences
ROIV
|
+$29.5M |
| 4 |
Boston Scientific
BSX
|
+$26M |
| 5 |
Merck
MRK
|
+$20.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$64.8M |
| 2 |
Intuitive Surgical
ISRG
|
+$37.9M |
| 3 |
Teva Pharmaceuticals
TEVA
|
+$31.2M |
| 4 |
Penumbra
PEN
|
+$31.1M |
| 5 |
Teleflex
TFX
|
+$30.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EVMN
76
Evommune Inc
EVMN
$511M
| $5.17M | 0.25% |
225,000
+100,000
| +80% | +$2.26M |
|
77
Acadia Healthcare
ACHC
$2.96B
| $4.68M | 0.22% |
+200,000
| New | +$3.62M |
|
78
Zimmer Biomet
ZBH
$18.7B
| $4.52M | 0.22% |
+50,000
| New | +$4.59M |
|
79
Forte Biosciences
FBRX
$1.57B
| $3.88M | 0.19% |
+150,000
| New | +$4.32M |
|
|
LBRX
80
LB Pharmaceuticals
LBRX
$1.31B
| $3.7M | 0.18% |
150,000
+50,000
| +50% | +$1.15M |
|
81
Savara
SVRA
$1.17B
| $3.28M | 0.16% |
+600,000
| New | +$3.34M |
|
82
Relmada Therapeutics
RLMD
$484M
| $3.13M | 0.15% |
+450,000
| New | +$2.13M |
|
83
Immunocore
IMCR
$1.73B
| $3.02M | 0.14% |
+100,000
| New | +$3.24M |
|
|
MAZE
84
Maze Therapeutics
MAZE
$1.51B
| $2.98M | 0.14% |
100,000
| – | – |
|
85
Tenax Therapeutics
TENX
$51.6M
| $2.67M | 0.13% |
167,000
| – | – |
|
86
Inhibikase Therapeutics
IKT
$386M
| $2.27M | 0.11% |
1,350,000
-400,000
| -23% | -$710K |
|
87
Olema Pharmaceuticals
OLMA
$1.04B
| $2.24M | 0.11% |
+150,000
| New | +$3.34M |
|
|
IVA
88
Inventiva
IVA
$1.12B
| $2.22M | 0.11% |
+400,000
| New | +$2.44M |
|
|
SION
89
Sionna Therapeutics
SION
$203M
| $2M | 0.1% |
+50,000
| New | +$1.91M |
|
90
Unicycive Therapeutics
UNCY
$138M
| $1.48M | 0.07% |
+225,000
| New | +$1.47M |
|
|
ACLX
91
DELISTED
Arcellx
ACLX
| – | – |
-200,000
| Closed | -$13M |
|
92
Alnylam Pharmaceuticals
ALNY
$29B
| – | – |
-60,000
| Closed | -$23.9M |
|
|
APLS
93
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-200,000
| Closed | -$5.02M |
|
94
BioCryst Pharmaceuticals
BCRX
$2.51B
| – | – |
-200,000
| Closed | -$1.56M |
|
95
Bruker
BRKR
$8.58B
| – | – |
-125,000
| Closed | -$5.89M |
|
96
Charles River Laboratories
CRL
$13.2B
| – | – |
-45,000
| Closed | -$8.98M |
|
97
Doximity
DOCS
$4.57B
| – | – |
-400,000
| Closed | -$17.7M |
|
98
Encompass Health
EHC
$12.5B
| – | – |
-100,000
| Closed | -$10.6M |
|
99
EyePoint Inc
EYPT
$1.13B
| – | – |
-200,000
| Closed | -$3.65M |
|
100
Gossamer Bio
GOSS
$86.1M
| – | – |
-1,000,000
| Closed | -$3.1M |
|
Similar funds
CL
ACM
ACG
NSUP
TP
ACP
TA
AG
Integral Health Asset Management's Q1 2026 Portfolio in Review
As of Q1 2026, Integral Health Asset Management held 114 positions worth $2.09B, up 3.8% from $2.01B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Integral Health Asset Management deployed $113M of net new capital in Q1 2026, opening 28 new positions and adding to 33 existing holdings. Its largest new stake was Alumis Inc: 800,000 shares worth $17.6M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 98% a quarter earlier.
On the sell side, the largest reduction was Intuitive Surgical, an estimated $37.9M trimmed.
- Integral Health Asset Management's largest Q1 2026 buy was Alumis Inc: 800,000 shares worth $17.6M.
- Integral Health Asset Management added most to Insmed in Q1 2026, an estimated $38.4M increase.
- Integral Health Asset Management's biggest Q1 2026 reduction was Intuitive Surgical, cutting an estimated $37.9M.
- Integral Health Asset Management fully exited Medtronic in Q1 2026, selling an estimated $64.8M.
- Integral Health Asset Management's ten largest holdings make up 45% of its $2.09B portfolio in Q1 2026.
- Integral Health Asset Management opened 28 new positions and closed 24 in Q1 2026.
- Integral Health Asset Management's portfolio value rose 3.8% quarter-over-quarter to $2.09B.
Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.